Biopharmaceutical company focused on developing targeted therapies for cancer.
Cullinan Oncology Inc. is a pioneering biopharmaceutical company dedicated to advancing a robust pipeline of targeted oncology and immuno-oncology therapies for cancer patients across the United States. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cullinan Oncology is at the forefront of developing innovative treatments that address significant unmet needs in oncology.
At the heart of Cullinan Oncology's portfolio is CLN-081, an orally available small molecule currently undergoing Phase I/IIa dose escalation and expansion trials. This lead candidate aims to revolutionize treatment options for patients with non-small cell lung cancer by targeting specific molecular pathways.
The company's preclinical pipeline includes a diverse array of promising candidates such as CLN-049, a humanized bispecific antibody targeting acute myeloid leukemia; CLN-619, a monoclonal antibody tailored for solid tumor therapy; and CLN-617, a fusion protein designed for treating solid tumors. Additionally, Cullinan Oncology is advancing CLN-978, a T cell engaging antibody focused on B-cell malignancies.
In pursuit of innovation, Cullinan Oncology has established strategic collaborations. These include partnerships with Cullinan Pearl Corp. for the development, manufacturing, and commercialization of CLN-081 and related products, and with Adimab, LLC for antibody discovery and optimization. With a commitment to pioneering cancer therapies, Cullinan Oncology continues to drive forward its mission to transform the landscape of oncology treatment.